Navigation Links
CareFusion Issues Update Regarding Previously Disclosed June 12, 2009 Recall of the Alaris(R) System
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire/ -- CareFusion Corporation, which is expected to become a public company following its planned spinoff from Cardinal Health, today issued the following update regarding its previously disclosed recall of the Alaris System:

On June 12, 2009, the company sent an urgent Medical Device Recall Notification to customers of its Alaris(R) System addressing potential risks identified with the Alaris System. The affected devices have one or more failures associated with the Occlusion Warning Message, Syringe Volume Warning Message, Electrostatic Discharge protection circuitry, and Fluid Ingress into the device's pumping mechanism. This recall also updates the labeling for the Inter Unit Interface (IUI) connectors on the Alaris(R) System. The potential risks may lead to improper infusion therapy, which could cause serious adverse health consequences or death.

Serial numbers of affected devices, as well as CareFusion's short term instructions to customers, and the firm's strategy to fix the affected devices can be found at: www.cardinalhealth.com/alaris/medical-device-recall/.

Following the FDA's 510(k) clearance of the firm's software correction in July 2009, CareFusion is now implementing corrections for units in the field.

In addition, CareFusion today began sending customers using the Alaris Patient Controlled Analgesia (PCA) module an update to the June 12, 2009, Medical Device Recall Notification. The update contains an additional required action to mitigate potential risk before completion of the field corrective action related to the Syringe Volume Warning Message that may appear while using the Alaris PC unit with the Alaris PCA module. The additional step involves removing the patient-controlled dose request handset from the patient prior to reprogramming the infusion pump.

"Implementation of the corrective action plan is an important area of focus for CareFusion and our customers, to ensure our medical devices in the field are operating as safely and effectively as possible," said Dwight Winstead, chief operating officer of CareFusion. "We continue to work closely with the FDA under our new quality system with the goal of manufacturing and supporting products that are among the safest in the industry."

The company recorded an $18 million reserve in its 2009 fiscal third quarter for all actions related to the corrective action plan and continues to believe the amount to be sufficient to fulfill its remediation obligations.

Instructions to customers

Customer inquiries related to this action should be addressed to the CareFusion recall center at 888-562-6018. Additional information about the recall can be found at www.cardinalhealth.com/alaris/medical-device-recall/.

CareFusion will work with customers to minimize disruption while correcting units at their facilities.

In the interim, customers should follow steps outlined in the June 12 Medical Device Recall Notification and the updated Notification for customers using the Alaris PCA module to minimize potential risk before implementation of the software and hardware updates.

CareFusion notified customers by registered letter on June 12, 2009, posted the customer letter on the company's web site and set up a dedicated call center for customer support. The FDA has also been apprised of this action.

Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA 5600 Fishers Lane, Rockville, MD 20852-9787, or at www.fda.gov/medwatch.

About CareFusion Corporation

CareFusion Corporation, a wholly owned subsidiary of Cardinal Health (NYSE: CAH), is expected to become a public company with the planned spinoff of the clinical and medical products businesses of Cardinal Health. The global company serves the health care industry with products and services that help hospitals measurably improve the safety and quality of healthcare. CareFusion develops market-leading technologies including Alaris((R)) IV pumps, Pyxis((R)) automated dispensing and patient identification systems, AVEA and Pulmonetic Systems(TM) ventilation and respiratory products, ChloraPrep((R)) for infection prevention and MedMined(TM) services for infection surveillance, neurological monitoring and diagnostic products, V. Mueller((R)) surgical instruments and an extensive line of products that support interventional medicine.

CareFusion employs more than 15,000 people across its global operations. The company has been authorized to have its shares of common stock listed on the New York Stock Exchange under the ticker symbol "CFN." More information may be found at carefusion.com.


'/>"/>
SOURCE CareFusion Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareFusion Form 10 Registration Statement Declared Effective
2. CareFusion Expands Pyxis(R) Perioperative Solutions Offering
3. CareFusion Prices $1.4 Billion of Senior Notes
4. Cardinal Health Board of Directors Approves CareFusion Spinoff
5. CareFusion to Resume Shipping Alaris(R) Infusion Products
6. CareFusion Corporation Launches International Jazz Festival Series
7. CareFusion Files Amended Form 10 Registration Statement With SEC
8. CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety
9. CareFusion Names Robert Friel to Board of Directors
10. CareFusion Announces Board of Directors, Progress on Alaris Consent Decree
11. CareFusion Names Edward Borkowski as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... Carefree, AZ (PRWEB) , ... February 10, 2016 , ... ... coach in new book , Pioneering book "Better with Age: The Ultimate Guide to ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – ... – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman University, will ... night, Feb. 8, prior to the evening session of the university’s 80th Annual Bible ... Camp, has been named director. Gayle McDonald, currently the assistant director of MSYC, will ...
(Date:2/10/2016)... ... ... It’s that time of year when most people have forgotten all about their New ... (IAAM), Hall of Fame athlete and Garrison Forest School athletic director since 2005, knows ... of her first decisions when her IAAM two-year presidency began last July was to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... MINNEAPOLIS , Feb. 10, 2016 Urologix, ... for the treatment of Benign Prostatic Hyperplasia (BPH), announces ... Ash Keswani , a medical device industry veteran ... of the Limited Liability Company.  ... and service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... -- Oxis International Inc. (OTC/QB: OXIS) announced today that the ... "clinical trial triumph" after one of the first patients ... Daniel Vallera , a research scientist ... --> Daniel Vallera , a research scientist ... --> An article on the University of ...
Breaking Medicine Technology: